Immunomodulatory effects
We analyzed the treatment effect on the peripheral blood lymphoid and myeloid compartments, as well as serum cytokine levels by evaluating these at screening, at the start of cycle 3, and at the end of treatment visit. Luo et al. recently described a small increase in Treg frequency one month after patients started on rivoceranib 500 mg daily [We analyzed peripheral blood lymphocyte expression of a panel of immune checkpoints, as well as costimulatory receptors and markers of activation (Additional file We did not find significant changes in serum cytokine levels while on rivoceranib and pembrolizumab (Additional file 